<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hereditary haemorrhagic <z:hpo ids='HP_0001009'>telangiectasia</z:hpo> (HHT), or <z:e sem="disease" ids="C0039445" disease_type="Disease or Syndrome" abbrv="">Rendu-Osler-Weber syndrome</z:e>, is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical manifestations are <z:hpo ids='HP_0000421'>epistaxis</z:hpo>, mucocutaneous and gastrointestinal <z:hpo ids='HP_0001009'>telangiectases</z:hpo>, and <z:hpo ids='HP_0100026'>arteriovenous malformations</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>There are two predominant types of HHT caused by mutations in Endoglin (ENG) and activin receptor-like kinase 1 (ALK1) (ACVRL1) genes, HHT1 and HHT2, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>No cure for HHT has been found and there is a current need to find new effective drug treatments for the disease </plain></SENT>
<SENT sid="4" pm="."><plain>Some patients show severe <z:hpo ids='HP_0000421'>epistaxis</z:hpo> which interferes with their quality of life </plain></SENT>
<SENT sid="5" pm="."><plain>We report preliminary results obtained with <z:chebi fb="0" ids="8772">Raloxifene</z:chebi> to treat <z:hpo ids='HP_0000421'>epistaxis</z:hpo> in postmenopausal HHT women diagnosed with <z:hpo ids='HP_0000939'>osteoporosis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>We tried to unravel the molecular mechanisms involved in the therapeutic effects of <z:chebi fb="0" ids="8772">raloxifene</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>ENG and ACVRL1 genes code for proteins involved in the transforming growth factor beta pathway and it is widely accepted that haploinsufficiency is the origin for the pathogenicity of HHT </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, identification of drugs able to increase the expression of those genes is essential to propose new therapies for HHT </plain></SENT>
<SENT sid="9" pm="."><plain>In vitro results show that <z:chebi fb="0" ids="8772">raloxifene</z:chebi> increases the protein and <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of ENG and ALK1 in cultured endothelial cells </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="8772">Raloxifene</z:chebi> also stimulates the promoter activity of these genes, suggesting a transcriptional regulation of ENG and ALK1 </plain></SENT>
<SENT sid="11" pm="."><plain>Furthermore, <z:chebi fb="0" ids="8772">Raloxifene</z:chebi> improved endothelial cell functions like tubulogenesis and migration in agreement with the reported functional roles of Endoglin and ALK1 </plain></SENT>
<SENT sid="12" pm="."><plain>Our pilot study provides a further hint that oral administration of <z:chebi fb="0" ids="8772">raloxifene</z:chebi> may be beneficial for <z:hpo ids='HP_0000421'>epistaxis</z:hpo> treatment in HHT menopausal women </plain></SENT>
<SENT sid="13" pm="."><plain>The molecular mechanisms of <z:chebi fb="0" ids="8772">raloxifene</z:chebi> involve counteracting the haploinsufficiency of ENG and ALK1 </plain></SENT>
</text></document>